Beijing Hotgen Biotech Co Ltd
SSE:688068
Gross Margin
Beijing Hotgen Biotech Co Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | CN |
Market Cap | 2.8B CNY |
Gross Margin |
51%
|
Country | US |
Market Cap | 230B USD |
Gross Margin |
40%
|
Country | US |
Market Cap | 192B USD |
Gross Margin |
58%
|
Country | US |
Market Cap | 44.3B USD |
Gross Margin |
51%
|
Country | US |
Market Cap | 42B USD |
Gross Margin |
35%
|
Country | KR |
Market Cap | 55.6T KRW |
Gross Margin |
49%
|
Country | CH |
Market Cap | 36.7B CHF |
Gross Margin |
36%
|
Country | US |
Market Cap | 32B USD |
Gross Margin |
59%
|
Country | IE |
Market Cap | 26.1B USD |
Gross Margin |
30%
|
Country | US |
Market Cap | 25.9B USD |
Gross Margin |
37%
|
Country | US |
Market Cap | 21.3B USD |
Gross Margin |
60%
|
Profitability Report
View the profitability report to see the full profitability analysis for Beijing Hotgen Biotech Co Ltd.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Beijing Hotgen Biotech Co Ltd's most recent financial statements, the company has Gross Margin of 50.6%.